Stem cell treatment for long-lasting chest pain not helped by meds
Part of Heart & circulation, Pain clinical trials.
This Phase 2 trial tests whether stem cells placed into the heart artery can safely reduce symptoms in people with “refractory” angina (chest pain) despite maximum heart-healthy medication. You may qualify if your chest pain is limiting your activity and other heart procedures (stents/bypass) aren’t possible or are too risky.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have ongoing chest pain from blocked heart arteries for at least 90 days despite max heart medications
- Have tried at least two types of anti-angina medicines at the highest tolerated doses for 2+ months and keep the plan steady for 12 months after randomization
- Have no good option for stent or bypass surgery, or your doctors say you’re too high-risk for it
- Have proof of reduced blood flow to the heart that can be triggered during a stress test (or by medication), and your treadmill test can last 2–8 minutes
- Have heart pumping strength (left ventricle ejection fraction) of at least 30% within the last 12 months, and be able to consent and attend follow-ups
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy (XC001) delivered through a thin tube into your heart's blood vessels. It aims to grow new blood vessels to relieve chest pain in people with chronic angina who have no other treatment options.
This trial tests whether a small pressure-reducing device placed in a heart vein (the coronary sinus) can reduce symptoms in people with ongoing chest pain from tiny blood vessel problems. It is for angina that has not improved despite standard heart medicines, and only if special heart tests show reversible reduced blood flow.
This trial tests whether implanting a small device in the heart’s coronary sinus can reduce symptoms in people with long-lasting “refractory” angina despite taking the usual heart medicines. It may help improve how much activity you can do and reduce angina-related limitations.
This trial tests a device called the Neovasc Coronary Sinus Reducer to help people with long-lasting, hard-to-control chest pain (angina) who cannot have artery-opening procedures. It may improve symptoms by changing blood flow in the heart’s vein system.
This study tests a new stem cell treatment for people with widespread coronary artery disease (narrowing of heart blood vessels) that causes chest pain. The treatment aims to improve blood flow and reduce symptoms, even for those who are not good candidates for other procedures.
This trial tests if umbilical cord stem cells, given alongside standard care, can help people who have had a major heart attack (STEMI). The cells are infused into the heart artery to possibly improve heart function. You may qualify if you are between 20 and 76, had a heart attack within the last 12 hours, and received a stent, and your heart's pumping ability is moderately reduced.
Hear when a new Refractory Angina trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.